Characteristics of convalescent plasma donors for Covid-19: Barriers for consent
Researcher Bulletin of Medical Sciences,
Vol. 27 No. 1 (2022),
20 Aban 2022
,
Page e17
Abstract
Background and Objective: Covid-19 pandemic is a worldwide bothersome issue. Although the appropriate strategy for plasma donation from recovered Covid-19 cases should be based on clinical, laboratory, and demographic characteristics of cases, consent for plasma donation is crucial. Moreover, the safety of donation is important not only for receiving cases but also for donor subjects. Accordingly in this study, the existing conditions in plasma donors for Covid-19 were assessed.
Materials and Methods: In this descriptive cross-sectional study, 264 consecutive cases with positive Covid-19 infection history were enrolled in 2020 a total of 64 cases were eligible for plasma donation. The initial two stages for consent and medical history were done by phone call and two final steps including laboratory results and physical examination were carried out after patients’ attendance to the hospital.
Results: Mean (standard deviation) age was 45.3 (9.1) years. There were 58 male cases (90.6%). Totally 70.3% had academic literacy and 90.6% were married. Even thirteen cases (20.3%) had underlying diseases. There was not any significant early or late complication during donation. Causes for plasma donation were mentioned help to humankind, severe disease experience, and help to research projects in 41 (64.1%), 14 (21.8%), and 9 (14.1%) cases, respectively.
Conclusions: It is necessary to inform the post-covid-19 patient about the advantages of plasma donation as a safe way for critically ill patients to decrease the burden of the disease in their current condition without confirmed drugs.
- Covid-19; Pandemics; Convalescent plasma; Donation
How to Cite
References
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020 May;55(5):105955.
https://www.worldometers.info/coronavirus/.
Huang Q, Deng X, Li Y, Sun X, Chen Q, Xie M, et al. Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. Int J Clin Pharm [Internet]. 2020/05/14. 2020 Jun;42(3):837–45. Available from: https://pubmed.ncbi.nlm.nih.gov/32410206
Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, et al. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med. 2021 Apr;49(4):598–622.
M Cascella, M Rajnik, A Aleem, S C. Dulebohn RDN. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls [Internet]. 2021;
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398–400.
Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis [Internet]. 2005 Jan;24(1):44–6. Available from: https://pubmed.ncbi.nlm.nih.gov/15616839
Ko J-H, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617–22.
Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. Vol. 357, The New England journal of medicine. United States; 2007. p. 1450–1.
Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Vol. 158, Chest. 2020. p. e9–13.
Li L, Tong X, Chen H, He R, Lv Q, Yang R, et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion. 2020 Aug;60(8):1765–72.
Tedder RS, Semple MG. Appropriate selection of convalescent plasma donors for COVID-19. Lancet Infect Dis [Internet]. 2020/06/15. 2021 Feb;21(2):168–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32553190
Guarente J, Amadio G, Marie Chang A, Doxzon K, Harach M, Hegarty S E, Henwood P, Karp J K, Kemp, M, Leiby B E, Peedin A R, Pettengill M RKL. Characteristics of COVID-19 convalescent plasma donors and antibody levels. Transfusion. 2020;60(5):284A.
Characterization of SARS-CoV-2 Antibody Titers in over 6,000 Blood and Plasma Donations.
Shinar E, Izak M, Cohen D, Stuoyanov E, Paran N, Israeli T, Axelrod O, Chen J, Maor Y ZO. Preliminary Data on the First Group of Convalescent COVID-19 Plasma Donors in Israel.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA [Internet]. 2020 Apr 28;323(16):1582–9. Available from: https://doi.org/10.1001/jama.2020.4783
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study. medRxiv [Internet]. 2020 Jan 1;2020.03.16.20036145. Available from: http://medrxiv.org/content/early/2020/03/23/2020.03.16.20036145.abstract
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr;117(17):9490–6.
Cheraghali AM, Abolghasemi H, Eshghi P. Management of COVID-19 Virus Infection by Convalescent Plasma. Vol. 19, Iranian journal of allergy, asthma, and immunology. Iran; 2020. p. 3–6.
- Abstract Viewed: 360 times